SBC Medical Group Holdings Inc., a Japanese owner and operator of aesthetic medical clinics, has officially entered the U.S. market through a strategic investment in OrangeTwist, a U.S.-based medspa chain. This move represents the beginning of SBC's full-scale strategic expansion in the United States and is part of a broader multiyear roadmap to establish leadership positions in key international markets. The partnership will enable joint operations between the companies, leveraging synergies in both the U.S. and Asian markets.
OrangeTwist operates 24 locations across six U.S. states and specializes in non-invasive aesthetic treatments including injectables, energy-based procedures, and regenerative therapies. SBC cited OrangeTwist's advanced management system, which integrates procurement, clinical workflows, and real-time KPI tracking, as providing operational consistency that supports scalable growth. Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings, stated that OrangeTwist has solidified its leadership in the U.S. market by consistently delivering exceptional quality and outstanding client experiences in non-invasive aesthetic medicine.
The U.S. market represents a significant growth opportunity for SBC Medical Group. According to company reports, the medical aesthetics industry is forecast to grow from $34 billion today to $48 billion by 2030. Drivers of this growth include increasing demand for non-surgical treatments like injectables, fillers, laser treatments, and body contouring that offer minimal risk and downtime, along with demographic factors such as the aging U.S. population seeking aesthetic treatments. This expansion follows SBC's existing Southeast Asian strategy, including an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics in Thailand.
During 2026, SBC Medical plans to make additional strategic investments and partnerships similar to the OrangeTwist arrangement to expand its presence in both the U.S. and Southeast Asia. The company's expansion plan is structured in three phases: Phase 1 involves strategic investments and partnerships like the OrangeTwist deal; Phase 2, scheduled for 2027 and 2028, will focus on select acquisitions and joint ventures to accelerate growth; and Phase 3, beginning in 2029, aims to establish leadership positions in the U.S., Southeast Asia, and other key markets. Robert Settembro, CEO of OrangeTwist, expressed enthusiasm about deepening the strategic partnership with SBC Medical Group while expanding presence in high-growth markets.
The importance of this development lies in the consolidation and globalization of the medical aesthetics industry, where established international players are entering high-growth markets through strategic partnerships. For consumers, this could mean greater access to standardized aesthetic treatments and potentially new product developments through the companies' planned collaboration on beauty products and services. For the industry, it signals increased competition and potential acceleration of service innovation as global expertise combines with local market knowledge. The deal provides SBC Medical with an immediate operational foothold in the lucrative U.S. market while giving OrangeTwist access to SBC's global network and expertise, creating a competitive advantage in a rapidly expanding industry landscape.
